论文部分内容阅读
在过去的十年中,外周血管扩张药已广泛地用于严重慢性充血性心衰病人的治疗,但是人们在实践中发现:根据传统的按药物作用部位来对血管扩张药进行分类,并不能为慢性心衰病人提供满意的药物治疗方案。为此,近年来国外又提出一个新的药物分类法。这种新的分类方法是根据药物的作用机制而不是主要作用的外周部位。它将外周血管扩张药分成二类:①直接作用于血管的激动剂,如肼苯哒嗪、硝普钠、硝酸盐类和长压定等;②神经激素拮抗剂,如哌唑嗪、trimazosin、酚妥拉明、SQ20881(Teprotide)和甲巯丙脯酸(captopril)等。
Peripheral vasodilators have been used extensively in the treatment of patients with severe chronic congestive heart failure over the past decade, but it has been found in practice that classification of vasodilators according to the traditional site of action does not Chronic heart failure patients with satisfactory drug treatment programs. To this end, in recent years abroad has proposed a new drug taxonomy. This new classification method is based on the mechanism of action of the drug rather than the main role of the peripheral site. It divides the peripheral vasodilators into two categories: (1) agonists acting directly on blood vessels such as hydralazine, sodium nitroprusside, nitrates and nifedipine; and ② neurohormonal antagonists such as prazosin and trimazosin , Phentolamine, SQ20881 (Teprotide) and captopril and the like.